The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Leukemia

Volumn 15, Issue 10, 2001, Pages 1537-1543

  Blagosklonny, M V ^a   Fojo, T ^a   Bhalla, K N ^b   Kim, J S ^a   Trepel, J B ^a   Figg, W D ^a   Rivera, Y ^a   Neckers, L M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bcr Abl; Chemotherapy; Cytoprotection; Gendanamycin; HSP90; Oncogenes

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTOTOXIC AGENT; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL NUCLEUS; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DESENSITIZATION; DRUG ANTAGONISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0034771555     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402257     Document Type: Article

References (37)

1. Fused transcript of abl and bcr genes in chronic myelogenous leukemia
2. The molecular biology of chronic myeloid leukemia
3. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
4. The BCR gene and Philadelphia chromosome-positive leukomogenesis
5. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
6. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
7. BCR-ABL delays apoptosis upstream of procaspase-3 activation
8. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
9. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with upregulation of Bcl-xL
10. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
11. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X
12. Kinases: Positive and negative regulators of apoptosis
13. Inhibition of HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
14. Conformation of mutated p53 requires functional HSP90
15. The HSP90 antagonist geldanamycin alters chaperone association with p210BCR-ABL and v-src proteins prior to their degradation by the proteasome
16. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL
17. Depletion of ErbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
18. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
19. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death
20. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
21. Mitogen-activated protein kinase pathway is dispensible for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
22. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
23. Dysregulation of apoptosis in cancer
24. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148
25. Effect of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
26. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells
27. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents
28. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemia drugs
29. Efficacy of STI 571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
30. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI 571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
31. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
32. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
33. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
34. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI 571: Diverse mechanisms of resistance
35. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents
36. Heat shock proteins - Modulators of apoptosis in tumour cells
37. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs